QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=9A6DB3B64EC4691E87DB5822539F917C;jsessionid=021395EE77A032A88963306DAA958A91;jsessionid=376A6CA3B658921F7406128C79062411;jsessionid=F38BCB351FA95B8B2DF4BDD673AED71E;jsessionid=926B1245AD127A01DC67BA069AC04291;jsessionid=082E710AF4072A0AAE18BA206A7D35BA;jsessionid=0F984CB8DF2DC5897D5ECAEE9D2C413E;jsessionid=166770DECE2F222DC8ECAA5C073E4CF3;jsessionid=DFFD3CBB79079CC06BCFD24DC907ACB9 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Identification of novel regulatory NFAT and TFII-I binding elements in the calbindin-D28k promoter i…

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=9A6DB3B64EC4691E87DB5822539F917C;jsessionid=021395EE77A032A88963306DAA958A91;jsessionid=376A6CA3B658921F7406128C79062411;jsessionid=F38BCB351FA95B8B2DF4BDD673AED71E;jsessionid=926B1245AD127A01DC67BA069AC04291;jsessionid=082E710AF4072A0AAE18BA206A7D35BA;jsessionid=0F984CB8DF2DC5897D5ECAEE9D2C413E;jsessionid=166770DECE2F222DC8ECAA5C073E4CF3;jsessionid=DFFD3CBB79079CC06BCFD24DC907ACB9